Soluble PD-L1-secreting umbilical cord-derived mesenchymal stromal cells transiently attenuate established xenogeneic T cell activation in vivo

Ryosuke Uchibori, Ken Ohmine, Keiya Ozawa · 2026

Read Soluble PD-L1-secreting umbilical cord-derived mesenchymal stromal cells transiently attenuate established xenogeneic T cell activation in vivo by Ryosuke Uchibori, Ken Ohmine, Keiya Ozawa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473534.txt.

Description

Ryosuke Uchibori and two colleagues tested in 2026 whether engineered stem cells could calm an active human immune response in mice. Mesenchymal stromal cells can suppress immunity, but their effect depends on priming and fades after intravenous infusion, because cells lodge in the lungs. The team engineered umbilical cord-derived cells to secrete soluble PD-L1, a checkpoint molecule that lowers T-cell activation without cell contact. They tested them in mice carrying human immune cells with established activation.

Ordinary cord or bone marrow cells did not restrain the established response. The engineered cells blunted activation during dosing without reducing T-cell numbers. A blocking antibody partly reversed the effect, supporting a PD-1/PD-L1 mechanism. Imaging showed lung trapping with short-lived exposure to the molecule. The authors conclude that timing, location, and amount of exposure limit such cell therapies, and that checkpoint delivery can offer only temporary immune calming.

Catalog record

CREATORRyosuke Uchibori, Ken Ohmine, Keiya Ozawa
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13473534

Browse the full library · About the Tower of Babel